Page 3 - I Mab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from I mab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In I Mab Today - Breaking & Trending Today

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization. ....

United States , Hong Kong , South Korea , Lin Shen , San Diego , Gigi Feng , Andrew Zhu , Richard Yeh , Prnewswire The Company Nasdaq , Cancer Hospital Of Peking University , Exchange Commission , Drug Administration , Lifelink Oncology Research Institute , Clinical Oncology , Beijing Cancer Hospital , Peking University , Link Oncology Research , Orphan Drug Designation , Private Securities Litigation Reform Act , Operating Officer , Chief Financial , I Mab ,

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients immune system against cancer cells.. ....

United States , Hong Kong , Qing Zhou , Long Wu , San Diego , Andrew Zhu , Richard Yeh , Gigi Feng , Guangdong Academy Of Medical Sciences , Exchange Commission , Prnewswire The Company Nasdaq , Guangdong Lung Cancer Institute , American Society Of Clinical Oncology , Clinical Oncology , Principal Investigator , Guangdong Provincial People , Guangdong Academy , Medical Sciences , Guangdong Lung Cancer , Toripalimab Combination Therapy , Trial Results Using , Potential Predictive Biomarker , Private Securities Litigation Reform Act , Operating Officer , Chief Financial , I Mab ,

I-Mab (NASDAQ:IMAB) Short Interest Up 8.6% in April

I-Mab (NASDAQ:IMAB – Get Rating) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 2,020,000 shares, an increase of 8.6% from the March 31st total of 1,860,000 shares. Based on an average daily volume of 399,000 shares, the short-interest ratio […] ....

Piper Sandler , Acadian Asset Management , Mission Capital , Needham Company , Sei Investments Co , Get Rating , Asset Management , Point Capital Management , I Mab Daily , I Mab , Nasdaq Imab ,

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization. ....

United States , Qing Zhou , Hong Kong , San Diego , Mccormick Place , Gigi Feng , Richard Yeh , Exchange Commission , Mccormick Place Convention Center , Prnewswire The Company Nasdaq , American Society Of Clinical Oncology , Clinical Oncology , Annual Meeting , Toripalimab Combination Therapy , Trial Results Using , Potential Predictive , Guangdong Provincial People , Private Securities Litigation Reform Act , Operating Officer , Chief Financial , I Mab ,

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon s. ....

San Diego , United States , Hong Kong , Richard Yeh , Gigi Feng , Michael Sitrick Los Angeles , Andrew Zhu , Exchange Commission , Prnewswire The Company Nasdaq , Pharmaceuticals Tracon , Bsab Agreement , Securities Litigation Reform Act , Operating Officer , Chief Financial , Los Angeles , New York , I Mab ,